Market Cap
$245.9M
MGNX
MACROGENICS INC
$3.61 ▲ +0.14%
Prev close $3.60Market cap$245.9M
ConsensusBuy
12-mo target$8.00 (+121.9%)
▲ Bullish
Analyst conviction 6/10
High Impact Filing (7/10)19 New Institutional Positions8 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on MGNX right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Buy (64%)
Inst. Holders
50 funds
Inst. Value
$173.2M
Inst. Activity
19 buys / 8 sells
Insider Activity
$0.00 buy / $129.1K sell
Insider Net $
-$129.1K
SEC Reports
8
Press Releases
3
Price chart 30d -16.6%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 19, 2026 Insider
Peters Jeffrey Stuart sold 31,105 shares
Senior VP, GC, and Secretary @ $4.15 ($129.1K)
Aug 17, 2026 Insider
Bonvini Ezio acquired via exercise 40,000 shares
Sr VP, Research & CSO @ $2.60 ($104.0K)
Aug 12, 2026 earnings_calendar
Jul 8, 2026 SEC MGNX Q2 2026 Earnings Scheduled — 2026-08-12
Karen Ferrante, M.D. resigned from the board of MacroGenics for personal reasons, effective September 1, 2026. The depar
8-K — Impact 2/10
MacroGenics completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million, transitio
Impact 6/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
4,679,229 shares ($21.6M)
Jun 30, 2026 Inst.
Jun 12, 2026 SEC WASATCH ADVISORS LP — ADD
2,018,881 shares ($9.3M)
A mixed institutional cluster formed in MGNX during Q3 2024: 5 smaller managers modestly added ($411K net buying), while
INST-CLUSTER — Impact 6/10
Analyst ratings buy % +18.5%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
64% rate it Buy or better · 14 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 17, 2026 | B. Riley Securities | MAINTAIN | Buy | 54% |
| Apr 20, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Apr 10, 2026 | B. Riley Securities | UPGRADE | Buy | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 6 | 5 | 0 | 0 | 64% | |
| Aug 1, 2026 | 3 | 5 | 5 | 0 | 0 | 62% | |
| Jul 1, 2026 | 3 | 5 | 5 | 0 | 0 | 62% | |
| Jun 1, 2026 | 3 | 5 | 5 | 0 | 0 | 62% | |
| May 1, 2026 | 3 | 5 | 5 | 0 | 0 | 62% | |
| Apr 1, 2026 | 3 | 4 | 6 | 0 | 0 | 54% | |
| Mar 1, 2026 | 3 | 4 | 6 | 0 | 0 | 54% | |
| Feb 1, 2026 | 3 | 4 | 6 | 0 | 0 | 54% |
Price targets
Where 4 covering analysts think MGNX trades over the next 12 months.
$8.00 +121.9% upside Strong Buy
Current$3.61 Low$4.00 Median$8.50 High$11.00 4 analysts
$4.00$11.00
Analyst rating Buy· 2.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 4 bullish, 0 bearish, 1 mixed, 3 neutral · avg impact 5.0/10.Plus 3 press releases.
NEUTRAL8-K2/10
Karen Ferrante, M.D. resigned from the board of MacroGenics for personal reasons, effective Septembe
Jul 8, 2026
MIXEDINST-CLUSTER6/10
A mixed institutional cluster formed in MGNX during Q3 2024: 5 smaller managers modestly added ($411
Jun 12, 2026
NEUTRALINST-CLUSTER3/10
Four institutions increased their MGNX positions in Q3 2025 while one reduced, resulting in net buyi
Jun 11, 2026
BULLISH8-K7/10
MacroGenics reported Q1 2026 revenue of $20.8M (up 57% YoY) and net loss of $36.8M, essentially in l
May 13, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 12, 2026
earnings_calendar
MGNX Q2 2026 Earnings Scheduled — 2026-08-12
Aug 11, 2026
earnings_calendar
MGNX Q2 2026 Earnings Scheduled — 2026-08-11
Jul 31, 2026
short_interest_report
Short Interest: MGNX up 29% to 7.3M shares
Settlement 2026-07-31 | Days to cover: 9.33 | ≈11.55% of shares outstanding (est.)
Jul 23, 2026
announcement
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
ROCKVILLE, MD, July 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing in
Jul 2, 2026
announcement
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
ROCKVILLE, MD, July 02, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing in
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.13 | $-0.17–$-0.08 | -147.1% | +59.3% | 0↑ 1↓ | $0.0B | 2 |
| Next Q | $-0.35 | $-0.35–$-0.35 | -57.5% | -22.3% | 0↑ 1↓ | $0.0B | 1 |
| Current FY | $-1.56 | $-3.20–$-0.28 | -32.0% | -132.3% | 1↑ 3↓ | $0.1B | 7 |
| Next FY | $-1.47 | $-1.70–$-1.23 | — | -3.7% | 0↑ 1↓ | $0.1B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.127 | — |
| 7d ago | $-0.270 | +0.143 |
| 30d ago | $-0.313 | +0.185 |
| 60d ago | $-0.313 | +0.185 |
| 90d ago | $-0.313 | +0.185 |
Institutional ownership
Which big funds own MGNX (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $173.2M total value (37,491,669 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, RENAISSANCE. Net buying activity: 19 institutions added/increased vs 8 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 4,679,229 | $21.6M | 12.5% | DOUBLED +302.3% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,656,010 | $12.3M | 7.1% | — |
| RENAISSANCE TECHNOLOGIES LLC | 2,632,750 | $12.2M | 7.0% | ADD +71.0% |
| BANK OF AMERICA CORP /DE/ | 2,488,252 | $11.5M | 6.6% | ADD +30.7% |
| TWO SIGMA INVESTMENTS, LP | 2,465,699 | $11.4M | 6.6% | — |
| MILLENNIUM MANAGEMENT LLC | 2,374,296 | $11.0M | 6.3% | ADD +41.5% |
| WASATCH ADVISORS LP | 2,018,881 | $9.3M | 5.4% | ADD +29.4% |
| RA CAPITAL MANAGEMENT, L.P. | 1,864,176 | $8.6M | 5.0% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1,820,231 | $8.4M | 4.9% | ADD +50.6% |
| MACKENZIE FINANCIAL CORP | 1,642,626 | $7.6M | 4.4% | DOUBLED +174.9% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | DOUBLED | 1,163,146 | 4,679,229 | +302.3% | $21.6M |
| WASATCH ADVISORS LP | ADD | 1,559,701 | 2,018,881 | +29.4% | $9.3M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 1,208,775 | 1,820,231 | +50.6% | $8.4M |
| MACKENZIE FINANCIAL CORP | DOUBLED | 597,442 | 1,642,626 | +174.9% | $7.6M |
| GEODE CAPITAL MANAGEMENT, LLC | DOUBLED | 697,321 | 1,576,549 | +126.1% | $7.3M |
| JACOBS LEVY EQUITY MANAGEMENT, INC | DOUBLED | 441,143 | 1,002,274 | +127.2% | $4.6M |
| STATE STREET CORP | DOUBLED | 293,687 | 863,663 | +194.1% | $4.0M |
| GOLDMAN SACHS GROUP INC | DOUBLED | 273,478 | 558,001 | +104.0% | $2.6M |
| NORTHERN TRUST CORP | DOUBLED | 152,282 | 516,129 | +238.9% | $2.4M |
| DIMENSIONAL FUND ADVISORS LP | ADD | 251,803 | 379,335 | +50.6% | $1.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
16 insiders, 50 transactions. Net -$129.1K — $0.00 bought, $129.1K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 19, 2026 | Peters Jeffrey Stuart | Senior VP, GC, and Secretary | SELL | 31,105 | $4.15 | $129.1K |
| Aug 17, 2026 | Bonvini Ezio | Sr VP, Research & CSO | EXERCISE | 40,000 | $2.60 | $104.0K |
| May 19, 2026 | Koenig Scott | Director | AWARD | 22,000 | — | — |
| May 19, 2026 | Ferrante Karen Jean | Director | AWARD | 3,750 | — | — |
| May 19, 2026 | HURWITZ EDWARD | Director | AWARD | 22,000 | — | — |
| May 19, 2026 | Ferrante Karen Jean | Director | AWARD | 22,000 | — | — |
| May 19, 2026 | Koenig Scott | Director | AWARD | 3,750 | — | — |
| May 19, 2026 | STUMP DAVID C | Director | AWARD | 3,750 | — | — |
| May 19, 2026 | STUMP DAVID C | Director | AWARD | 22,000 | — | — |
| May 19, 2026 | HURWITZ EDWARD | Director | AWARD | 3,750 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for MGNX.
Shares short
7,032,428
Settlement Sep 15, 2026
Change vs prior
-1.3%
Semi-monthly cycle
Days to cover
15.7
At avg daily volume
Of shares outstanding
≈11.0%
Estimate — not % of float
All MGNX filing & press-release reports (11)
- 8-K reportJul 8, 2026
- PRESS-RELEASE reportJul 2, 2026
- INST-CLUSTER reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 13, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 11, 2026
- 8-K reportApr 8, 2026
- PRESS-RELEASE reportApr 8, 2026
- DEFA14A reportApr 8, 2026
- INST-CLUSTER reportFeb 28, 2026